





Principles of an EMR Uamuzi Bora HIV EMR








Uamuzi Bora

- Based on MOH257
- >10,000 patients registered
- Scaleable model to other sites
- and to MCH...



COMPREHENSIV	/E CARE CLINIC PATIENT CARD MOH 257
PATIENT PROFILE:	ARV THERAPY
Unique Patient Number : Date of Birth Age: Sex Male Femile Postal Address :	Date Medically Eligible Eligible thru.? Clinical TLC CD4 (count/% WHO Stage
Tel Contact: District: Location:	COHORT: MONTH YEAR(e.g Jan 2006)
Sub-location: Nearest School	Date Started on 1st Line Regimen: Regimen: Regimen: At Start of ART: WHO Stage
Nearest H/Centre: Marital Married Polygamous Divorced Cohabiting Status: Married Monogamous Widowed Single Treatment Supporter: Name: Relationship:	Substitution of ARVs within 1st Line Regimen Dates Regimen Reason(s)
Postal Address: Tel No:	Date Started on 2 nd Line Regimen: Regimen: Reason(s)
Patient Source Entry Point PMTCT VCT TB OPD In-Patient Child Welfare Clinic	Substitute of ARVs Within 2 nd Line regimeni Dates Regimen Reason(s)
Others (Specify eg STI) Transfer in: Date: From: District:	Transfer Out and Death
Facility: Date started ART:	Date Event Where?
ART History Previously on ARVs (PMCT included)? List Drug Date let led	Patient Transferred Out Patient Died
If "Yes" then Names & Dates Last Used	
b)	ART Treatment Interruptions Dates Reason for Interruption Date Restarted
Date Confirmed HIV + Where? Date Enrolled in HIV Care WHO Stage Date PEP offered Reason for PEP Any Known Drug Allergies?	
Reasons for PEP: REASONS FOR TREATMENT INTERRUPTION 1. Sexual assault 1. Default (1/12) 2. Occupational exposure 2. LOST to follow-up (3/12) 3. Others (Specify) 3. STOP	WHY SUBSTITUTE CODES 1. Toxicity/side effects 2. Pregnancy 3. Risk of pregnancy 4. Due to new TB 5. New drug available 6. Drug out of stock 7. Other responsion processors REASONS FOR SWITCH TO 2ND LINE REGIMEN ONLY 1. Clinical treatment fallure 2. Immunologic failure 3. Virologic failure 3. Virologic failure


Unique Patient Nu	mber	П	11	П		INI	TAL AND FOLLOW	UP VISITS				М	ОН 257
Date						1"							1
						1		i	1				
						1 1							1
Wt										and the same of			
(KgI)		b		-	-								
Height(for children)	Ms)			150 mm	75 135								
Prognant : Yes/No, Gestation (wk/s), EDD	, PMCT?												
FP status If Yes = ONFP them of If No=NOFP	enter Method												
TB Status							7500						
New OI,											\rightarrow		
Other medical Conditi	QM3												
ART Side effects							2						
			-	-						-			-
Cotrimoxaxole - Y/N,	Adherence	-	-								_		-
Cocrimotatore - 1714,	WHY?			-							_		+
Tuconazale- Y/N,													
raconnectic, 1/14, /	WHY?									-			
Other medications													+
The state of the s													
		-		0					-		1		1
Adho	rence? WHY?												
							1						
ARV drugs				DL.									
	Regimen						1						
				y ====									4
CD4/% ,/ Results										lane (according			1
				- 000									-
HB, Results												_	-
ALT, Results		<u> </u>							_	_			-
Other lab tests & re	suits "			-	-				_		_		-
									_	_	_		-
Referred To?											_		-
If hospitalized, No.	of days					-							+
Date of Next appointm											1		+
Clinicians initials													
The state of the s					Name of the last								-
TB Status(On each visit):	Codes for ART apolicable)	RT side effects (Grade where Codes for OI or other med		s for OI or other medical co	onditions:- Codes for why a		Codes for why unsatisfactory adherence:			(cotrimoxaz	ole,		
1.NO signs		1.Peripheral neuropathy		1. Zo	sler	11. Weight loss	Toxicity/side effects		10 Alcohol	fluconazole or ART]	T	Weeed	
2.TB suspected	2. Rash 3. Ansemia 4. PAncrestitis 5. Jaundice 6. FAT redistribution			eumonia	12. UD urethral discharge 13. PID petric inflammatory disease	Forgot Fett better Too ill Stigma, disclosure or privacy issues		11 Depression 12. Share 13. Other	Adherence	*	Dosse per		
3.TB RX				mentia/Enceph							Month		
				rush—oral/vaginal					S(Satisfactory)	≥ 95%	≤3 doses		
				cers-mouth, etc					S(SECTION Y)	2 80 W	2300		
	7. Hypersensit					DUGH	14.GUD genital	Prug stock out—dispensing area Patient lost/ran out of pits Delivery/bavel problems			Minnestation	4000	12 days
	8. HEpatotoxic					difficult breathing	ulcerative disease				U(unsatisfactory)	< 95%	> 3 doses
	9. CNS: dzzy.		htmare, de	pression	9. IRI	S Immune reconstitution		9 Inability to pay					
						flammatory syndrome		, ~ , ~ ,					





COMPREHENSIV	E CARE CLINIC PATIENT CARD	MOH 257				
PATIENT PROFILE:	ARV THERAPY					
Unique Patient Number : Date of Birth Age: Sex Male Femile Postal Address :	Date Medically Eligible Eligible thru.? Clinical WHO Stage	TLC CD4 (count/%				
Tel Contact: Location:	COHORT: MONTH YEARIE.g Jan 2006) Date Started on 1st Line Regimen: Regimen: At Start of ART: WHO Stage					
Sub-location: Nearest School						
Nearest H/Centre: Marital Married Polygamous Divorced Cohabiting Status: Married Monogamous Widowed Single Treatment Supporter: Name: Relationship:	Substitution of ARVs within 1st Line Regimen Regimen	Reason(s)				
Postal Address: Tel No:	Date Started on 2 nd Line Regimen:	Regimen: Reason(s)				
Patient Source Entry Point PMTCT VCT TB OPD In-Patient Child Welfare Clinic Others (Specify eg STI)	Substitute of ARVs within 2 nd Line regim Dates Regimen	Reason(s)				
Transfer In: Date: From: District:	Transfer Out and Death					
Facility: Date started ART:	Date Event	Where?				
ART HISTORY Previously on ARVs (PMCT included)? List Drug If "Yes" then Names & Dates Last Used	Patient Transferre Patient Died	ed Out				
b)	ART Treatment Interruptions Dates Reason for Inter	ruption Date Restarted				
Date Confirmed HIV + Where? Date Enrolled in HIV Care WHO Stage Date PEP offered Reason for PEP Any Known Drug Allergies?						
Reasons for PEP: REASONS FOR TREATMENT INTERRUPTION Sexual assault 1. Default (1/12) 2. Occupational exposure 2. LOST to follow-up (3/12) 3. Others (Specify) 3. STOP	1. Toxicity/side effects RE 2. Pregnancy 1. C 3. Risk of pregnancy 2. Is	ASONS FOR SWITCH TO 2ND LINE GIMEN ONLY linical treatment failure turnunologic failure irologic failure				


HEALTH FACILITY FORM	REPUBLIC OF KENY	YA - MINIS	TRY OF HEALTH HIV/AIDS, MALARIA, TB a	nd CHILD NUTRITION	3000	MOH 711A
	FRACILITY KMUSANDI		MONTH: JULY		YEAR:	
DISTRICT: NAME CENTER NAME C	P PAGESTY.	OTHER STATE	G: TB	Children Adults TOT.		15-24 years 2.25 years TOT/
			No. of Till cases detected		Country	32 9 43 20 10
Incomp	ATA VISIT	2210	Ing as	rta o	1. Clients Tooled	35 8 3 74 19
THEOTHE		IIDD	III Sade	000	No of Tested	5
2 NUECTIONS SUSCIONS	32 89	121	S. No. of	00000	Z. cougles Both HIVV	0
A main ANTS Insertion	0 0	0	Total No. of TB Patients NIVe	0 0 0 0 0	Steconlent	Children Adults
Incorre	ct codi	100	B. No. of YB HIV patients on CPT B. No. of defaulters	8 8 0 0 0	E DTC	(0-14 yrs) (>14yrs) TOT
III COLLE		112	10. (all forms of TB)	00112	No. Counselled In-Paties	14 7 114 69 21
E TOTAL NO. OF CLIENTS	34 97	10	11 No of TS depths	00000	2 No tested Outpatie	14 7 114 69 1
8 REMOVALS: IUCD 10Th - 114	IMPLANTS [3. No selve Outpatie	0022
B MCH-ANC/ No New Re-visit TOTAL	C: MATERNITY-PMCT	TOTAL	C SHOWTH MONITORING		a onowin mountaines	00000
• Data er	itry err	Or	Chinas Heading Fathers on	E M 20744	Chindren Reading Face	W. 10 M 101A
5. No. of Charter press PT (2" does) 2.5	3. Women aund HIV+ , No. of a formen issued with		- Markettus Emaktenber	0 0	Value 0.25.90	
5. No. of Clients completed 4th Antennetal Visit 6. No. of ITNs distributed to ANC clients	preventive ARVs No. of infant Preventive	(A Areania	6 2 2	Distance (A.S.)	7 9 17
2. No. of ANC clients Tested for HIV	5. ARVs administered 6. Total Deliveries from HIV+ women	17	. Faltering Str.	0 0 0	0.11.00	123 145 26
1000	7. No initiated Women cotrimoxaxole Infants	1	Others a g. Witgenin A. stafficiating, with (Spanish))	AND DESCRIPTION OF THE PERSON	Weight 33:30	164 101 25
5. No. of claims Found +ve	E: MATERNITY / SAFE DELIVERIES	NUMBER			dren	
St. No. of officerts insued with proventive ARVs No. of infants At 5 was.	1. Normal Deliveries	NUMBER	K: ART	0.1	6yrs Adults >14yrs	Totals Gran
(t. HOV+ referred for Mothers	Cassarean Sections Breech Delivery			PMCT clients 0	3	F M
12. No. of infants issued with preventive ARVs	4. Assisted vaginal delivery	0	No of new patients enrolled within the	TB nationts	500	0000
13. No. of mothers counseled on infant feeding Options	5. TOTAL DELIVERSES 6. Live Sinha	1	month for HIV care by entry point	In patients CWC All others	8 9	8 8 8
14. No. of partners Tested (7. Still Births g. Under Weight Babies	7	2 Complaints No. of persons	Sub-total and HIV care of	8 6 1	By 1 3"
1991	8. (Weight below 2500 grams) 9. Pre-Term babies	7	this facility at end of the mo	WHO steps 1	2 8/3 19	85 21 106
D: STI Type of Females Males Total	10. No. of bables discharged alive	1	Number of patients 2 starting ARV's within the	WHO stage 2	8 8 8	8 8 8
States	11. Referrals 12. Neonatal Deaths		month by WHO stage	Sub-total O	0 0 1	81 1 2
Comman of Continual Institute years Co.	13. Maternal Deaths		 Cumulative No. of persons i facility at end of the month. 	0	1 12 7	12 8 20
States Returns 0 0 0	Maternal complications 14. A.P.H. (Ante Partum	Alive Dead	5. Total No. of patients currently on ARVs	Pregnant woman All others Sub-total	I R T	11 8 19
1 Special Secret Special Secret Special Specia	Harmorrhage)	1	No. of persons who are enro ART but have not been start	unt sidingle box bello	0 1 1	11 8 19
A Common Dyposite Marketings O O O	16. Eclampela	12	, Post exposure	Sexual assault	0 0 0	0 0 0
1 Grand Totals 0 0 0	17. Reptured Uterus 18. Obstructed lateur	4	prophylasis[PEP]	Occupational All others Sub-total	0000	0 0 0
F: PAC SERVICES TOTAL	19. Sepala		a. Total No. of patients currently on prophylaxis	Cotrimovazole 2	2 87 23	89 25 118
2 No. of Back				Sub-total 2	2 88 23	90 25 115
2 may be to the			L. BLOOD SAFETY I. Blood units collected from	Regional Blood Transfusion Centers	NUMBER BU	DOD SAFETY (cont.) NUMBE
Chromat 2000 10 25743 -31			2. Blood unds collected from	other sources Other than Regional Bloom		Blood units screened found HEVE Blood units screened for Hocotic B
Prepared By Samuel Solla	318/10		Bood units screened at to Bood Units translated	mater facility	7.	Blood units screened for Populitie C Blood Units screened for Byphile
Uate:	Destroy Destroy	11-14 1	THE CANADA			Stone Paris Robbins or State

			MINIS	TRY OF HEA	LTH				
		COMPREHENS	IVE CARE C	LINIC MON	THLY SUMM	ARY SHEET			
				1/					
acility Nam	e: Kakamega PGH CCC								_
ite Code:	15915.0	Manning Agangu	MoH				From:	01/Jan/197	
ite Code:	13915.0	Manning Agency:	МОП				FIOIII.	01/Jan/19/	
ype:	Government	District:	Kakamega	Province:	Western		To:	23/Nov/201	2
ypc.	GOTCHINICITE	District	Rukumegu	TTOTINGE:	Western		10.	25/1101/202	-
	Measure	Children	(0-14yrs)	Adults >	14 yrs	To	tals	Grand Total	
ID	Measure	•	М	F	М	F	М	F	
	1	PMTCT	6			502	44	508	55
		VCT	79	81	1,622	2,813	1,701	2,894	4,59
	THE RESIDENCE OF THE PROPERTY OF THE PERSON	TB patients	12	14	88	119	100	133	23
	No of new patients enrolled	Inpatients	4	5	198	293	202	298	50
Α	within the month for HIV	Outpatients	32			189	162	235	
	care by entry point	CWC	2		2	3	4		
		All Others	137	141	532	870	669	1,011	1,68
	1	(missing)	25		149	290			50
		Sub-total	297			5,079			
В	Cumulative no of persons		356	380	5,205	2,823	5,561	3,203	8,764
В	ever enrolled in HIV care at		356	380	5,205	2,823	5,561	3,203	8,764
	10	WHO stage 1	11			197	100		
	Number of patients starting	WHO stage 2	42		293	641	335		1,02
C	ARVs within the month by	WHO stage 3	25	31	353	550	378	581	95
-	WHO stage	WHO stage 4	2	2	46	46	48	48	9
	WHO stage	(missing)	31	32	397	631	428	663	1,09
	1	Sub-total	111	131	1,178	2,065	1,289	2,196	3,48
	0.0000000000000000000000000000000000000					-			5
D Cun	Cumulative no of persons		104	120	1,110	1,966	1,214	2,086	3,300
D	ever started on ARV at this		104	120	1,110	1,900	1,214	2,000	3,300
							1		
1 - 1	Total No. of patients	Pregnant women	,	3	S	132		135	
E	currently on ARVs	All Others	104	117	1,110	1,834	1,214	1,951	3,16
732	currently on ARVS	Sub-total	104	120	1,110	1,966	1,214	2,086	3,30
	No of persons enrolled and		56	53	519	874	575	927	1,502
F	eligible for ARVs but not yet		30	33	313	074	373	72,	1,502
	Total no of patients	Sexual assault							3
G	currently on post exposure	Occupational							
	prophylaxis (PEP)	All others			54 A				
	propriyidals (FET)	Sub-total	0	0	1	0	1	0	
						1.5:-			
н	Total no of patients	Cotrimoxazole	328	355	2,612	4,848	2,940	5,203	8,14
	currently on prophylaxis	Fluconazole							
		Sub-total	328	355	2,612	4,848	2,940	5,203	8,14

















Data verification












Missing data










Clinical reminders











Follow-Up











Summary



Data verification

Clinical reminders

Programs eg. Follow Up







Our model

